ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Integrative Transcriptomic Profiling Delineates LTBP4-Driven Fibroblast Reprogramming Across the Ossification Continuum of the Ligamentum Flavum.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To delineate the dynamic transcriptomic landscape of ossification of the ligamentum flavum (OLF) across normal, immature, and mature stages, identify core genes, and screen stage-specific drug candidates. Normal, immature, and mature OLF tissues (nine samples) from three patients with multilevel OLF were collected for RNA-seq. Differential expression, functional enrichment, and dynamic trend analyses were performed. Key genes were validated using an external GEO dataset. Single-cell and spatial transcriptomics were integrated to determine cellular origin and spatial localization. AI-based drug prediction and molecular docking were conducted. Between normal versus immature, 1026 DEGs were identified; between immature versus mature, 713 DEGs; and between normal versus mature, 1285 DEGs. Upregulated genes were enriched in RNA processing and ribosome biogenesis, whereas downregulated genes were enriched in ECM-receptor interaction. LTBP4 showed progressive downregulation during ossification (AUC = 0.88). Single-cell transcriptomics and spatial transcriptomic analysis of a public multi-omics dataset (GSE255942) revealed that LTBP4 is expressed in fibroblasts, with lower expression in ossified than normal tissues. Virtual knockout of Ltbp4 in fibroblasts recapitulated the OLF transcriptomic signature. AI-based drug prediction identified stage-specific candidates; BRD-K59831625 exhibited the lowest binding energy with LTBP4 (-8.9 kcal/mol). Sustained LTBP4 downregulation drives OLF progression, with fibroblasts as core effector cells. Stage-specific drug candidates were identified. These findings provide new targets for molecular diagnosis and precision treatment of OLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.